Erlotinib Completed Phase 1 Trials for Cancer, Advanced Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00895687Study of Erlotinib in Combination With Bortezomib
NCT00895128Study of Erlotinib in Combination With Dasatinib
NCT01287546A Study of LY2875358 in Participants With Advanced Cancer